行情

BLPH

BLPH

柏勒罗丰治疗
NASDAQ

实时行情|Nasdaq Last Sale

7.77
-0.06
-0.77%
已收盘, 16:58 01/21 EST
开盘
7.83
昨收
7.83
最高
7.94
最低
7.63
成交量
5.07万
成交额
--
52周最高
26.00
52周最低
3.186
市值
7,379.77万
市盈率(TTM)
-2.3462
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Global Nitric Oxide Therapy System Market 2020 Industry Overview, Competition by Manufacturers, Production Capacity by Region, Forecast by 2025
Jan 20, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has newly published research study entitled Global Nitric Oxide Therapy System Market 2020...
CDN Newswire · 1天前
Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 Healthcare Industry COVID-19 Impact Forecast By Size, Growth, Share Estimation, Business, And Global Trends Analysis To 2026
Jan 18, 2021 (The Expresswire) -- Inhaled Nitric Oxide (NO) Delivery Systems Market | 2021 COVID-19 Impact On Healthcare Industry Size, Growth Rate,...
The Express Wire · 4天前
8-K: Bellerophon Therapeutics, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/12 05:50
生物技术的未来一周（12月27日至1月2日）：数据发布，监管备案以转移库存
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K. The news flow of the week comprised mixed clinical trial readouts, COVID-19 drug and vaccine announcements, a few M&A announcements and a small-ticket IPO.
Benzinga · 2020/12/26 14:15
Mid-Afternoon Market Update: Dow Surges 250 Points; Bellerophon Therapeutics Shares Slide
Toward the end of trading Monday, the Dow traded up 0.89% to 29,522.86 while the NASDAQ rose 0.08% to 11,864.80. The S&P also rose, gaining 0.37% to 3,570.63.
Benzinga · 2020/11/23 19:35
Mid-Day Market Update: Nasdaq Edges Lower; DPW Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.53% to 29,417.20 while the NASDAQ fell 0.19% to 11,832.26. The S&P also rose, gaining 0.07% to 3,559.94.
Benzinga · 2020/11/23 17:17
Mid-Morning Market Update: Markets Open Higher; AstraZeneca Covid-19 Vaccine Shows Up To 90% Efficacy In Late-Stage Trials
Following the market opening Monday, the Dow traded up 0.61% to 29,442.35 while the NASDAQ rose 0.12% to 11,868.79. The S&P also rose, gaining 0.38% to 3,571.09.
Benzinga · 2020/11/23 15:41
Bellerophon Therapeutics Puts COViNOX Study Of INOpulse For COVID-19 On Clinical Hold
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing
Benzinga · 2020/11/23 13:32
更多
财务预测
每股收益每股净资产每股现金流
实际值（美元）
预测值（美元）
利润表更多
净利润营业总收入营业利润
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流（美元）
同比（%）
了解BLPH最新的财务预测，通过BLPH每股收益，每股净资产，每股现金流等数据分析柏勒罗丰治疗近期的经营情况，然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测BLPH价格均价为23.67，最高价位30.00，最低价为19.00。
EPS
机构持股
总机构数: 64
机构持股: 690.82万
持股比例: 72.74%
总股本: 949.78万
类型机构数股数
增持
14
16.88万
建仓
18
-3.49万
减持
8
8.21万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.04%
制药与医学研究
-0.53%
高管信息
Chairman/Director
Jonathan Peacock
Chief Executive Officer/Chief Financial Officer/Director
Fabian Tenenbaum
Chief Financial Officer/Secretary
Assaf Korner
Vice President - Operations
Parag Shah
Vice President
Martin Dekker
Vice President - Administration
Amy Edmonds
Other
Wassim Fares
Other
Peter Fernandes
Director
Ted Wang
Independent Director
Naseem Amin
Independent Director
Matthew Bennett
Independent Director
Scott Bruder
Independent Director
Mary Cloyd
Independent Director
Andre Moura
Independent Director
Crispin Teufel
Independent Director
Theodore Wang
  • 分红
  • 拆股
  • 内部人交易
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
BLPH 简况
Bellerophon Therapeutics, Inc.是一家临床阶段的治疗公司。该公司致力于开发满足心肺疾病医疗需求的药物和设备。该公司致力于开发治疗肺动脉高压（PH）的一氧化氮疗法，该疗法使用INOpulse输血系统，其中肺动脉高压（PAH）为主要指标。INOpulse设备具有在呼吸开始时定时产生短暂靶向脉冲一氧化氮的机制，以将一氧化氮递送到肺泡，这一机制最小化治疗所需药物量。该公司的另一个项目BCM是一种致力于预防伴随ST段抬高型心肌梗死（STEMI）的充血性心力衰竭的医疗设备，STEMI是一种严重的心脏病发作。该公司的BCM正处于临床试验PRESERVATION第一阶段。
展开

微牛提供Bellerophon Therapeutics Inc(NASDAQ-BLPH)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BLPH股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BLPH股票基本功能。